<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Peter K Moore | PlatCOVID</title>
    <link>/author/peter-k-moore/</link>
      <atom:link href="/author/peter-k-moore/index.xml" rel="self" type="application/rss+xml" />
    <description>Peter K Moore</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Fri, 22 May 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png</url>
      <title>Peter K Moore</title>
      <link>/author/peter-k-moore/</link>
    </image>
    
    <item>
      <title>Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection.</title>
      <link>/publication/32422349/</link>
      <pubDate>Fri, 22 May 2020 00:00:00 +0000</pubDate>
      <guid>/publication/32422349/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.</title>
      <link>/publication/32312290/</link>
      <pubDate>Thu, 23 Apr 2020 00:00:00 +0000</pubDate>
      <guid>/publication/32312290/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.</title>
      <link>/publication/32267998/</link>
      <pubDate>Wed, 08 Apr 2020 00:00:00 +0000</pubDate>
      <guid>/publication/32267998/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
